Regulatory notice

HospitalsAescia for Hospitals is an investigational Software as a Medical Device under the TGA Class IIa pathway. Not yet available for commercial supply.

ClinicsAescia for Clinics is a workflow and patient-preparation tool. It does not propose clinical decisions and is not a medical device.

For Clinics

Better prep. Fewer no-shows. Less phone work.

Pre-procedure pathways by text and email, with endoscopy as the first home. Diabetic, anticoagulant, and GLP-1 overlays. Recall that stops slipping. It does not propose clinical decisions and is not a medical device.

See a clinic demo See pricing posture

Posture

Not a medical device. Not a decision tool.

A workflow and patient-preparation platform. Does not diagnose, does not treat, does not propose clinical decisions.

What the levers are worth in the literature.

Ranges from randomised trials and benchmark datasets, not promises. Run your own numbers in the calculator below.

Prep adequacy

adequate prep for screening and surveillance colonoscopy with text-message navigation, up from 88%

Solonowicz 2022, randomised, n=1,625, US academic endoscopy unit

Attendance

non-attendance with text-message reminders before colonoscopy. US results are mixed, so we treat US transfer as pilot-to-prove.

Meta-analysis of 4 randomised trials, RR 0.74 (95% CI 0.56–0.99). Li 2022

Backfill

midpoint commercial facility fee per colonoscopy at a US surgery center. Billed, not margin.

Wang 2023, JAMA Health Forum, 17,052 ASC fee observations

Recall

of Medicare patients aged 70 and over had a repeat colonoscopy within five years of polypectomy

Cooper 2013, Cancer, n=12,771

Nine things that run the day-to-day.

Prep pathways that adapt

Pick the prep your clinic uses. The pathway adapts to the patient in front of it. Diabetic, IBD, constipation, prior-failed-prep, elderly, all covered without rewriting the page.

No-show reduction

Timed reminders in the patient language, a confirm-and-reschedule path built in, a same-day flag your front desk can actually act on. When a slot opens, a prep-ready backfill shortlist for the clinic to offer.

GLP-1 handling

Patient self-reports the medication and the dose. The pathway delivers the clinician-authored instruction that corresponds to the patient's report, aligned with the 2024 multi-society guidance and the 2025 international consensus. Decisions remain with the proceduralist.

Diabetic and anticoagulant overlays

SGLT2, metformin, DOAC, and warfarin scenarios delivered as clinician-authored instructions, generated from the patient's answers. The clinician signs off the rule set, not the vendor.

Prep-night photo review

The evening before, the patient can upload a toilet-bowl photo through the web-app. The pathway checks it against a clinician-set rubric and flags whether the prep looks on track, so the clinic can confirm or reschedule before the patient leaves home.

Call deflection

Two-way messaging by SMS and email answers the top twenty prep questions before they reach the front desk, using templated clinician-authored responses. The clinic sees the exceptions, not every message.

Surveillance and recall

High-risk polyp follow-up and surveillance intervals do not rely on a spreadsheet anyone might miss. Named patients, named dates, named triggers, aligned with USMSTF and NHMRC interval guidance.

Integration-friendly

Designed to sit alongside the systems your clinic already runs and to be quick to set up, without a second login for your team. We scope any data exchange with you.

Single-site friendly

Configured by one clinic admin in an afternoon. The platform is built to save more than it costs, so your site comes out ahead. Designed to go live in weeks once a champion is in place, not quarters.

Built for the ambulatory rhythm.

This is not a hospital discharge tool dressed for a clinic. It is a prep and workflow product with its own authored protocols, its own SMS layer, and its own vocabulary: today's list, room utilisation, case turnover, prep adequacy, recall compliance.

Today's listthe live schedule view

Room utilisationthroughput per room

Prep adequacyBoston Bowel Prep aligned

Recall compliancesurveillance interval tracking

Case turnovertime between completed procedures

Staff flagsexceptions your team still owns

Prep brands by region.

The pathway covers regional brand equivalents across the markets we support. Clinicians in each country see the prep names their patients see on the shelf.

United States: SuPrep, SuTab, CLENPIQ, GoLytely, NuLYTELY
Canada: PegLyte, PICO-SALAX, CLENPIQ, Bi-PEG-Lyte
Australia and New Zealand: Glycoprep, Picoprep, MoviPrep, Plenvu
United Kingdom and EU: Plenvu, Moviprep, Citrafleet

Specialties in scope.

Endoscopy is the first clinical focus: colonoscopy and gastroscopy pathway development is active, with regional bowel-prep variants and specialty overlays in build. The same engine extends to physiotherapy post-discharge, aesthetics, and other efficiency-seeking specialties as clinical champions join. If your specialty is not listed, we will build the pathway with you.

Colonoscopy

With regional prep variants and clinician-authored overlays

First focus

Gastroscopy

Pre-procedure fasting, meds review, GLP-1 overlay

First focus

Physiotherapy post-discharge

Elective orthopaedic, spinal, and joint pathways

On roadmap

Aesthetics and cosmetic

Consent, prep, photo capture, follow-up

On roadmap

Your specialty

If a clinical champion is in place, we build the pathway with you

Open

A fit for your practice?

What makes a specialty a good candidate.

We do not prescribe which specialties belong on the platform. We ask whether the friction is real, whether there is a clinician willing to co-author the pathway, and whether the patient journey has the kind of between-visit gap the engine can bridge.

01
A wait list under pressure
Long wait times, over-booked lists, or patients waiting weeks for a procedure where prep quality or no-shows are the rate-limiting step.
02
No-shows and cancellations eating throughput
Empty chairs, same-day cancellations, or inadequate preparation forcing repeat appointments. Any of these costs your team hours and the patient a delay.
03
Patient education and adherence between visits
Specialties where the weeks before or after an appointment carry risk: chronic disease, procedural prep, post-treatment monitoring, rehabilitation, lifestyle-dependent outcomes.
04
Direct clinician oversight, or hands-off
Some clinicians want every flag to route through them. Others want the pathway to handle the routine and surface only exceptions. The engine supports either, and the choice is set per pathway.
05
A clinician willing to author
Someone whose name goes on the rule set. The pathway is only as good as the clinician who authored it, and we do not ship one without a named author.

Talk to us about your specialty

Endoscopy ASC guides

Answers to the questions ASC buyers actually ask.

What software reduces colonoscopy no-shows at an ASC?What does endoscopy pre-procedure workflow software do?What software flags GLP-1 patients and adjusts prep?How are blood thinners and diabetes managed before a colonoscopy?How do I reduce the inadequate bowel prep rate?What is prep-aware waitlist backfill?How does Aescia differ from engagement and scheduling tools?Is Aescia right for your ASC?

Evidence stage

What the category has shown. What Aescia has not yet shown.

Published category evidence

Prep coaching, SMS reminders, and structured pre-procedure contact have a published evidence base.
The figures under the calculator are the load-bearing ones: Wang (facility fee per slot), Beran (inadequate prep is common and addressable), Lebwohl (downstream miss rate).
The calculator counts only late cancellations and no-shows, and credits backfill only on slots with about a day's notice.

Aescia is pre-first-customer

Aescia for Clinics has not published its own outcomes yet.
The Hospitals product is in clinical evaluation (SAFE-Discharge, Royal Prince Alfred Hospital), though that is cardiothoracic recovery, not endoscopy prep.
The calculator scales category literature to your site. Aescia-specific outcomes come from the design-partner pilots, measured against your own baseline.

How Aescia builds its pathways

Start from published guidelines: USMSTF and NHMRC (surveillance), multi-society guidance (GLP-1 peri-procedure), regional bowel-prep protocols, society anticoagulation guidance.
A practising clinician authors the rule set against those guidelines.
Rules are stress-tested on synthetic-patient cohorts before any real patient. Edge cases (diabetic and anticoagulated overlays, prior inadequate prep, GLP-1 with insulin) get resolved in the editor, not the front-desk queue.
Every pathway carries a named clinical author and a documented guideline trail.

How the design-partner pilots generate that evidence

The economics

Run your own numbers.

A busy endoscopy list loses more to cancelled prep, medication confusion, and follow-up drift in a week than Aescia costs for the month. The numbers below are yours, not ours. Set the four inputs to your ASC and the model rescales. Three honest bands, conservative through potential, anchored to the literature beneath.

Your numbers

Set the inputs to your own ASC. Defaults are an average US GI ASC and the US literature midpoints, sourced below. Every figure to the right rescales in real time.

Annual colonoscopy volume (scopes per year)

scopes

Late cancellation rate (about 24h notice)Cancellations that arrive late enough the slot would sit empty, but with about a day's notice, which is enough to backfill. Typical 3–8%. Same-day prep failures are not counted here because they cannot be refilled in time.

No-show rate (patient does not arrive)Common range: 5–15%. Separate from the late cancellation above, and not backfillable (no notice). Edit to your actual rate.

Recovered revenue per slot (USD)What a recovered slot bills, not margin. Wang 2023, Transparency in Coverage ASC range $989–$1,034 (n=17,052 ASC fees); default $1,011. Set yours; Medicare-heavy panels collect less.

Endoscopist professional fee per scope (USD)The proceduralist's professional fee per scope, separate from the facility fee above. Default $400 is a typical commercial colonoscopy professional fee (Medicare runs ~$220–300; commercial ~$300–500), about a 2.5:1 facility-to-professional ratio. Edit to your own rates. Drives the endoscopist loss line only, not the ROI multiple.

Late cancellations you refill todayShare of late cancellations your team refills now. Default 25%: short-notice slots are hard to fill without a prep-ready pool. Aescia credits only the lift above this.

Nurse time per patient on prep callsMinutes per patient your team spends on prep reminders and confirmations. Drives the staff-time line below; ~60% is automatable.

min

Inadequate bowel prep rateShare of your colonoscopies with inadequate or suboptimal prep. US real-world 10–25%; the 2025 USMSTF benchmark is at least 90% adequate, i.e. 10% or less. Drives the prep-recovery pool below.

Range of outcomes

Three bands tied to effect sizes from the literature. Aescia commits to no point estimate. Pilots are scoped to confirm where on the range your site lands.

Conservative

$185K/yr

Expected

$265K/yr

Potential

$343K/yr

Every month without Aescia is costing you ~$23.5K

~$15.4K for your ASC

~$4.6K for your endoscopists

~$2.8K for anesthesia

~$694 for pathology

Assumptions and sources are below.

Better prep means fewer repeat scopes

About $57K to $114K a year, from 56 to 113 fewer repeat or aborted procedures when prep goes right. Already folded into the figures above.

Bring back patients lost to follow-up

About $152K a year from roughly 150 overdue patients brought back, if your schedule has room. Works down a standing backlog rather than repeating yearly.

Assumptions for the above calculator

Late cancellation reduction: 0% / 10% / 20% (conservative / expected / potential). The trials that measured late cancellation directly are null, so the conservative band is 0% and the bands are anchored on their point estimates: Gaucher 2016 (AMBUPROG, PLoS One, randomised, n=3,900, 11 ambulatory surgery units) 5.6% vs 5.8%, adjusted odds ratio 0.91 (95% confidence interval 0.65–1.29); Keswani 2020 (Endosc Int Open, randomised, n=830, US) 17.7% vs 21.4%, odds ratio 0.8 (95% CI 0.6–1.1); El Bizri 2021 (PLoS One, meta-analysis of 10 randomised trials) odds ratio 0.96 (95% CI 0.68–1.35), I² = 0%. Expected and potential sit inside all three confidence intervals. Pilot-to-prove.
No-show reduction: 15% / 25% / 40%. Li 2022 (Int J Colorectal Dis, meta-analysis of 4 randomised trials) puts non-attendance at a risk ratio of 0.74 (95% CI 0.56–0.99), a 26% reduction with a 1–44% range, which is where the expected band sits. The individual trials that moved attendance ran outside the US: Lam 2020 (J Gastroenterol Hepatol, randomised, n=2,225, Hong Kong) 11.9% to 8.9% (p=0.022) with a text reminder, and Seoane 2020 (World J Gastroenterol, randomised, n=1,484, Spain) 14.3% to 8.4% with a nurse education call. Both US trials measured no change: Mahmud 2021 (JAMA Netw Open, randomised, n=753) on a nine-message text series and Keswani 2020 (Endosc Int Open, randomised, n=830) on patient-portal video. Treat the transfer to a US ASC as pilot-to-prove.
Prep-aware backfill rate on late cancellations: 55% / 65% / 75%, against a current rate you set (default 25%). The model credits only the lift over your current rate, on late cancellations only. Pilot-to-prove against your own baseline.
Prevention is netted by your current backfill: a late cancellation you would have refilled anyway is not counted as a recovered slot, so prevention and backfill do not double-count.
A recovered slot is valued at the recovered revenue (gross facility fee) you set, not contribution margin. The endoscopist professional fee, anesthesia and pathology are shown as separate full-episode lines and stay out of the facility figure and the ROI multiple, since anesthesia accrues to the anesthesia group and pathology to the lab.
Endoscopist professional fee: the per-scope figure you set drives the separate endoscopist loss line, on the same recoverable slots. Default $400 is a reasonable commercial professional fee for a colonoscopy — Medicare pays ~$220–300 (CPT 45378/45385 at the 2026 conversion factor) and commercial ~$300–500. Against the commercial facility fee that is about a 2.5:1 facility-to-professional split, the normal commercial range. Set both to your own rates.
Staff time is included in the figures above: 60% of your nurse prep-call minutes (default 20 min/patient) at $45/hr loaded. Treat it as the soft part of the range: it is real cash only if you redeploy the freed hours into more cases or a deferred hire.
Aescia is priced to cost less than the value above, so your site comes out ahead. Design partners start free and pay nothing until the platform proves that on your own data. Talk to us for your number.
Aescia commits to the conservative band in writing during design-partner pilots; the backfill lift is confirmed against your own baseline in the pilot.
Backfill applies to late cancellations only (about a day's notice). Same-day prep failures and no-shows are not backfillable, so they count toward prevention, never backfill. Late-cancellation default 3% and no-show default 5% sum to an 8% combined rate, matching the ASGE GI Operations Benchmarking combined no-show/cancellation metric (about 5.6–8.45%).
Beran 2024 (Am J Gastroenterol, n=358,257, 154 studies) anchors that inadequate prep is a common, upstream problem with addressable risk factors. Cancellation/no-show effect sizes are from the prep-coaching and SMS-reminder literature.
Facility fee: Wang 2023, Transparency in Coverage ($989–$1,034, n=17,052 ASC fees), commercial ASC fees for CPT 45378, 45380 and 45385.
Anesthesia: about $240/scope, the expected MAC-weighted figure (commercial roughly $410 per monitored-anesthesia case at about 58% utilization; Predmore 2019, USC Schaeffer 2021). Accrues to the anesthesia group, shown for the full-episode picture, not in the ROI multiple.
Pathology: about $60/scope expected, biopsy-weighted (CPT 88305 commercial about $82 per specimen, roughly 1.7 specimens on about 45% of scopes; PayerPrice 2026, GIQuIC). The softest figure here, and it accrues to the lab, not the ROI multiple.
Inadequate prep: default 15% of scopes (US real-world 10–25%; 2025 USMSTF benchmark 10% or less). Coaching, navigation and reminders cut it by 25% / 40% / 50% (Guo 2016, Tian 2021, Faveri 2025). About 30% of inadequate preps consume a repeat or aborted slot (GIQuIC 32% recommended within a year, VA 59% completed). This repeat recovery is folded into the recovered slots and the ROI above.
Surveillance recapture: roughly half of post-polypectomy patients are overdue or never return (US Medicare 5-year non-return ~54%; Cooper 2013, n=12,771; the model uses a conservative 48%). Reminders roughly double completion (Sci Reports 2021). Capacity-conditional and outside the ROI multiple.

The literature the calculator is anchored to.

Eight published figures the model relies on. They are listed here in plain text so a procurement reviewer, a clinical advisor, or a retrieval-augmented assistant can verify each one without operating the calculator.

Patients cancelled for presumed inadequate bowel preparation who completed a colonoscopy or stool test within six months: 67%
Facility-fee revenue lost per cancelled or repeated US ASC colonoscopy: USD $989–$1,034 per slot
Inadequate prep is common and largely predictable: 48 predictable risk factors
Adenoma miss rate on inadequate preparation: Up to 42%
Inadequate-prep colonoscopies flagged for a repeat within a year: ~1 in 3
Higher odds of adequate prep from enhanced instructions: 2.35× the odds
Medicare polypectomy patients with no surveillance colonoscopy within 5 years: 54%
Outpatient colonoscopy no-shows cut by SMS reminders: 11.9% → 8.9%

Public and modelled figures. Site-specific ROI requires a scoped evaluation against your own list volume, no-show rate, and prep-inadequacy baseline.

Pricing

We want you to come out ahead.

The platform is built to save you more than it costs and leave you better off than without Aescia. Design partners start free and pay nothing until it proves that on your own data. We want to be your partner and provide real value to your site.

See the design-partner program